Prof. Dr. Scott J. Antonia is a Professor of Medicine at the Duke University. He earned a PhD in Immunology from the University of Connecticut in 1987, and his MD from the University of Connecticut in 1989. He completed a residency in internal medicine and a fellowship in medical oncology from Yale University. He also received a post-doctoral fellowship in immunobiology from Yale University School of Medicine. He was the lead author of studies that have detailed the effectiveness of the novel immunotherapy treatments Imfinzi (durvalumab) and Opdivo for lung cancer. His lung cancer research has played a role in setting guidelines adopted and published by the National Comprehensive Cancer Network. His specialties are pleural mesothelioma, lung cancer, and immunotherapy.